newsfilter
← Latest News
GlobeNewswire·

Sagimet Biosciences Announces Dosing of First Participants in Phase 1 PK Clinical Trial for Denifanstat and Resmetirom Combination

Dosing has successfully commenced with healthy volunteersPrimary endpoints for the Phase 1 trial include safety, tolerability, and pharmacokinetic (PK) profile of the combinationTopline data are anticipated in the first